argenx SE/€ARGX
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx SE is a biotechnology company primarily engaged in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary SIMPLE Antibody™ platform to create differentiated immunology solutions. One of its flagship products is efgartigimod, designed to target the neonatal Fc receptor (FcRn) to modulate antibody levels, which has gained significant attention in therapeutic areas such as neuromuscular disorders. Founded in 2008, Argenx is headquartered in Ghent, Belgium, and has expanded its operations globally. The company's strategic positioning lies in its ability to combine deep insights into disease biology with cutting-edge technology to create novel treatments. Sources:
- Argenx Official Website: www.argenx.com
- "Argenx - Company Profile and News," Bloomberg, www.bloomberg.com
Ticker
€ARGX
Sector
Primary listing
BSE
Employees
1,599
Headquarters
Website
argenx SE Metrics
BasicAdvanced
€43B
43.75
€16.12
-
-
Price and volume
Market cap
€43B
52-week high
€733.00
52-week low
€459.00
Average daily volume
150
Financial strength
Current ratio
5.595
Quick ratio
4.92
Long term debt to equity
0.583
Total debt to equity
0.708
Interest coverage (TTM)
142.45%
Profitability
EBITDA (TTM)
403.336
Gross margin (TTM)
52.15%
Net profit margin (TTM)
41.03%
Operating margin (TTM)
14.83%
Effective tax rate (TTM)
-92.89%
Revenue per employee (TTM)
€1,677,070
Management effectiveness
Return on assets (TTM)
4.83%
Return on equity (TTM)
24.72%
Valuation
Price to earnings (TTM)
43.748
Price to revenue (TTM)
15.946
Price to book
7.04
Price to tangible book (TTM)
7.31
Price to free cash flow (TTM)
161.194
Free cash flow yield (TTM)
0.62%
Free cash flow per share (TTM)
4.376
Growth
Revenue change (TTM)
88.04%
Earnings per share change (TTM)
-640.89%
3-year revenue growth (CAGR)
177.34%
10-year revenue growth (CAGR)
78.53%
3-year earnings per share growth (CAGR)
2.74%
10-year earnings per share growth (CAGR)
28.75%
Bulls say / Bears say
U.S. FDA approved a prefilled syringe version of Vyvgart Hytrulo in April 2025, enabling at-home self-administration and expanding patient accessibility and market reach (Reuters)
argenx generated $949 million in global product net sales in Q2 2025, a 97% year-over-year increase, reflecting robust commercial execution and accelerating revenue growth (GlobeNewswire)
The pipeline continues to advance with ARGX-119 moving into a registrational study for chronic multifocal sensorimotor neuropathy following positive proof-of-concept data, underlining strong R&D momentum (GlobeNewswire)
Operating expenses for Q2 2025 rose to $766 million, up 43% from $535 million in Q2 2024, which could pressure operating margins despite strong revenue growth (GlobeNewswire)
Late-stage trial success by AstraZeneca’s gefurulimab in generalized myasthenia gravis introduces a potential high-profile competitor to Vyvgart, risking market share in key indications (Reuters)
Analyst price targets imply rich valuation multiples (e.g. Guggenheim’s $1,100 target), which may be difficult to sustain if Vision 2030 milestones slip or if R&D setbacks occur (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of €43B as of October 26, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 43.75 as of October 26, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) does not currently have a Beta indicator.